USE OF ASTRAGALUS MEDICINAL COMPOSITION FOR PREPARING DRUG FOR ENHANCING CANCER THERAPY

Abstract

A use of pharmaceutical composition for enhancing cancer treatment includes an Astragalus membranaceus extract and a mannose. The pharmaceutical composition can effectively enhance the effectiveness of chemotherapy drugs, thereby reducing cancer cell viability, and for drug resistant cancers. In addition, the pharmaceutical composition can also inhibit the growth of tumor cells.

Claims

1. A method for enhancing the treatment of a chemotherapy drug for a cancer in a subject for inhibiting the viability of a cancer cell, comprising administering to the subject an astragalus pharmaceutical composition, wherein the astragalus pharmaceutical composition comprises a refined astragalus polysaccharides (r-APS) and a mannose.

2. The method of claim 1, wherein the chemotherapy drug for the cancer is a targeted chemotherapy drug, wherein the targeted chemotherapy drug is a targeted chemotherapy drug for a corresponding cancer type.

3. The method of claim 1, wherein the cancer comprises colorectal cancer, ovarian cancer, or lung cancer.

4. The method of claim 2, wherein the targeted chemotherapy drug for the corresponding cancer type comprises Regorafenib, Olaparib or Tarceva.

5. The method of claim 1, wherein an effective dose ratio of the r-APS to the mannose is 1.5˜4.5:5.5˜8.5, and a concentration range of the astragalus pharmaceutical composition comprising the r-APS and the mannose is 0˜10 mg/mL.

6. The method of claim 1, wherein the form of the astragalus pharmaceutical composition can be tablet, pill, granule, powder, capsule, or liquid.

7. A method for enhancing the treatment of a chemotherapy drug for a cancer in a subject for treating a drug resistant cancer on inhibiting the viability of a cancer cell, comprising administering to the subject an astragalus pharmaceutical composition, wherein the astragalus pharmaceutical composition comprises a refined astragalus polysaccharides (r-APS) and a mannose.

8. The method of claim 7, wherein the chemotherapy drug for the cancer is a targeted chemotherapy drug, wherein the targeted chemotherapy drug is a targeted chemotherapy drug for a corresponding cancer type.

9. The method of claim 8, wherein the targeted chemotherapy drug for the corresponding cancer type comprises Regorafenib, Olaparib or Tarceva.

10. The method of claim 7, wherein the cancer is solid tumor cancer.

11. The method of claim 8, wherein the solid tumor cancer comprises colorectal cancer, ovarian cancer, or lung cancer.

12. The method of claim 7, wherein an effective dose ratio of the r-APS to the mannose is 1.5˜4.5:5.5˜8.5, and a concentration range of the r-APS and the mannose is 0˜10 mg/mL.

13. A method for enhancing the treatment of a chemotherapy drug for a cancer in a subject for inhibiting the proliferation of a tumor cell, comprising administering to the subject an astragalus pharmaceutical composition, wherein the astragalus pharmaceutical composition comprises a refined astragalus polysaccharides (r-APS) and a mannose.

14. The method of claim 13, wherein the tumor cell is a drug resistant tumor cell.

15. The method of claim 13, wherein the chemotherapy drug for the cancer is a targeted chemotherapy drug, wherein the targeted chemotherapy drug is a targeted chemotherapy drug for a corresponding cancer type.

16. The method of claim 15, wherein the targeted chemotherapy drug for the corresponding cancer type comprises Regorafenib, Olaparib or Tarceva.

17. The method of claim 13, wherein the tumor cell comprises colorectal cancer, ovarian cancer, or lung cancer.

18. The method of claim 13, wherein an effective dose ratio of the r-APS to the mannose is 1.5˜4.5:5.5˜8.5, and a concentration range of the astragalus pharmaceutical composition comprising the r-APS and the mannose is 0˜10 mg/mL.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0023] FIG. 1A shows that the results of the r-APS on drug resistant cell line of lung cancer (HCC827GR cells).

[0024] FIG. 1B shows that the results of the astragalus pharmaceutical composition comprising the r-APS and the mannose on drug resistant cell line of lung cancer (HCC827GR cells).

[0025] FIG. 1C shows that the results of Iressa as chemotherapy drug for lung cancer on drug resistant cell line of lung cancer (HCC827GR cells).

[0026] FIG. 2A shows that the results of the r-APS on drug resistant cell line of lung cancer (H1975 cells).

[0027] FIG. 2B shows that the results of the astragalus pharmaceutical composition comprising the r-APS and the mannose on drug resistant cell line of lung cancer (H1975 cells).

[0028] FIG. 2C shows that the results of Tarceva as chemotherapy drug for lung cancer on drug resistant cell line of lung cancer (H1975 cells).

[0029] FIG. 3A shows that the results of the r-APS in combination with Tarceva as chemotherapy drug for lung cancer on drug resistant cells of lung cancer (H1975 cells).

[0030] FIG. 3B shows that the results of the astragalus pharmaceutical composition comprising the r-APS and the mannose in combination with Tarceva as chemotherapy drug for lung cancer on drug resistant cell line of lung cancer (H1975 cells).

[0031] FIG. 4A shows that the select results of the 60˜70% chemotherapeutic inhibition cultured with cell line of colorectal cancer (HCT116 cells).

[0032] FIG. 4B shows that the results of cell line of colorectal cancer (HCT116 cells) cultured with the r-APS for 48 hours.

[0033] FIG. 4C shows that the results of cell line of colorectal cancer (HCT116 cells) cultured with the astragalus pharmaceutical composition comprising the r-APS and the mannose for 48 hours.

[0034] FIG. 4D shows that the results of cell line of colorectal cancer (HCT116 cells) cultured with the r-APS in combination with Regorafenib as chemotherapy drug for colorectal cancer for 48 hours.

[0035] FIG. 4E shows that the results of cell line of colorectal cancer (HCT116 cells) cultured with the astragalus pharmaceutical composition comprising the r-APS and the mannose in combination with Regorafenib as chemotherapy drug for colorectal cancer for 48 hours.

[0036] FIG. 5A shows that the select results of 60˜70% chemotherapeutic inhibition cultured with ovarian cancer cell line (OVCAR3 cells).

[0037] FIG. 5B shows that the results of ovarian cancer cell line (OVCAR cells) cultured with the r-APS for 48 hours.

[0038] FIG. 5C shows that the results of ovarian cancer cell line (OVCAR cells) cultured with the astragalus pharmaceutical composition comprising the r-APS and the mannose for 48 hours.

[0039] FIG. 5D shows that the results of ovarian cancer cell line (OVCAR cells) cultured with the r-APS in combination with Olaparib as chemotherapy drug for colorectal cancer for 48 hours.

[0040] FIG. 5E shows that the result of the astragalus pharmaceutical composition comprising the r-APS and the mannose in combination with Olaparib as chemotherapy drug for colorectal cancer cultured with ovarian cancer cell line (OVCAR cells) for 48 hours.

DETAILED DESCRIPTION OF THE INVENTION

[0041] The “r-APS” in the present invention refers to refined astragalus polysaccharides.

[0042] The enhancement of chemotherapy drug in the present invention is enhanced at least 16% of therapeutic effect.

[0043] The chemotherapy drug in the present invention comprises targeted chemotherapy drug, and the targeted chemotherapy drug is a targeted chemotherapy drug for corresponding cancer type.

[0044] The present invention provides a method for enhancing the treatment of a chemotherapy drug for a cancer in a subject for inhibiting the viability of a cancer cell, comprising administering to the subject an astragalus pharmaceutical composition, wherein the astragalus pharmaceutical composition comprises a r-APS and a mannose, wherein the ratio by weight of the r-APS to the mannose in the astragalus pharmaceutical composition is 1.5˜4.5:5.5˜8.5. The effective concentration range of the r-APS of the astragalus pharmaceutical composition in present invention is 0˜10 mg/mL, the effective concentration range of the mannose is 0˜10 mg/mL. Preferably, the effective concentration of the r-APS is 3 mg/mL, the effective concentration of the mannose is 7 mg/mL.

[0045] Further, the present invention also provides a method for enhancing or maintaining the treatment of a chemotherapy drug for a cancer in a subject for treating a drug resistant cancer on inhibiting the viability of a cancer cell, comprising administering to the subject an astragalus pharmaceutical composition, wherein the astragalus pharmaceutical composition comprises a r-APS and a mannose, wherein the ratio by weight of the r-APS to the mannose in the astragalus pharmaceutical composition is 1.5˜4.5:5.5˜8.5. The effective concentration range of r-APS in the astragalus pharmaceutical composition of the present invention is 0˜10 mg/mL, the effective concentration range of mannose is 0˜10 mg/mL. Preferably, the effective concentration of r-APS is 3 mg/mL, the effective concentration of mannose is 7 mg/mL.

[0046] Further, the present invention also provides a method for enhancing the treatment of a chemotherapy drug for a cancer in a subject for inhibiting the proliferation of a tumor cell, comprising administering to the subject an astragalus pharmaceutical composition, wherein the astragalus pharmaceutical composition comprises a r-APS and a mannose, wherein the weight ratio of the r-APS to the mannose in the astragalus pharmaceutical composition is 1.5˜4.5:5.5˜8.5. The effective concentration range of the r-APS in the astragalus pharmaceutical composition of the present invention is 0˜10 mg/mL, the effective concentration range of the mannose is 0˜10 mg/mL. Preferably, the effective concentration of the r-APS is 3 mg/mL, the effective concentration of the mannose is 7 mg/mL.

[0047] In some embodiments, the astragalus pharmaceutical composition is administered by injection, infusion, intravenous, or oral.

[0048] In some preferred embodiments of the present invention, the method for manufacturing the r-APS in present invention comprising the steps of:

(a) Put the astragalus chips in a container, add a pure water to form a solution A;
(b) Heat the solution A formed in step (a) at a time in 2-4 hours, the temperature is 80-100° C.;
(c) Collect and concentrate the solution of step (b) to obtain an extraction liquid A;
(d) Put the extraction liquid A of step (c) in a container B, add 30˜50% ethanol, stir and precipitate, collect and concentrate the supernatant to obtain a concentrated solution A;
(e) Add 75%˜95% ethanol in the concentrated solution A obtained in step (d), stir and precipitate, collect the precipitate A; and
(f) Dehydrate and filter the precipitate A of step (e), dissolve and precipitate with ethanol, centrifuge the precipitate to obtain product A, the product A contains r-APS.

[0049] Additional specific embodiments of the present invention include, but are not limited to the following:

Example 1

[0050] Influence of the r-APS and the Mannose on Drug Resistant Cells of Lung Cancer

[0051] This example discusses the influence of the r-APS and the mannose on the drug resistant cells of lung cancer, there are three test groups, respectively treated as follows:

(1) Test group 1: the different concentrations of the r-APS are 0.25 mg/ml, 0.5 mg/ml, 1 mg/ml, 2 mg/ml and 4 mg/ml.
(2) Test group 2: the different concentrations of the astragalus pharmaceutical composition comprising the r-APS and the mannose (hereinafter referred to as r-APS+mannose) (the ratio by weight of the r-APS:the mannose is 30%:70%) are 0.625 mg/ml, 1.25 mg/ml, 2.5 mg/ml, 5 mg/ml and 10 mg/ml.
(3) Test group 3: Iressa (applicable to the HCC827GR cell line) or Tarceva (applicable to the H1975 cell line).

[0052] The test group 1, test group 2 and test group 3 are added to the HCC827GR or the H1975 lung cancer cell line respectively, each group incubates for 24 hours, 48 hours and 72 hours respectively, and then the cell viability of the HCC827GR or the H1975 lung cancer cell line is tested. The results are shown in FIG. 1A˜1C and FIG. 2A˜2C.

[0053] The HCC827GR cell line is resistant to the chemotherapy drug Iressa for treating lung cancer, the result shows that the test group 2 (the r-APS) and test group 3 (the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose)) have better anticancer effect to lung cancer (as shown in FIG. 1A˜FIG. 1C).

[0054] The H1975 cell line is a cell line resistant to the drug Tarceva for treating lung cancer, the result shows that the test group 3 (the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose)) has the best anticancer effect (as shown in FIG. 2A˜FIG. 2C).

Example 2

[0055] Effect of the Astragalus Pharmaceutical Composition Comprising the r-APS and the Mannose (r-APS+Mannose) in Combination with Anticancer Drug on the Drug Resistant Cells of Lung Cancer

[0056] This example discusses the influence of the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose) on the drug resistant cells of lung cancer, there are three test groups, respectively treated as follows:

(1) Test group 1: the different concentrations of the r-APS are 0.25 mg/ml, 0.5 mg/ml, 1 mg/ml, 2 mg/ml and 4 mg/ml.
(2) Test group 2: the different concentrations of the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose) (the ratio by weight of the r-APS:the mannose is 30%:70%) are 0.625 mg/ml, 1.25 mg/ml, 2.5 mg/ml, 5 mg/ml and 10 mg/ml.

[0057] Each test group is used with Tarceva (concentrations are 1.25 μM, 2.5 μM and 5 μM) and added to H1975 lung cancer cell line respectively, each group incubates for 24 hours, 48 hours and 72 hours respectively, the cell viability of H1975 lung cancer cell line is measured.

[0058] The H1975 cell line is resistant to chemotherapy drug Tarceva, the result shows that the test group 1 (the r-APS) and test group 2 (the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose)) in combination with chemotherapy drug Tarceva have the best anticancer effect (as shown in FIGS. 3A-3B), meaning the test group 1 (the r-APS) and test group 2 (the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose)) in combination with chemotherapy drug Tarceva have the best therapeutic effect on reversing the drug resistance to anticancer drugs of lung cancer.

Example 3

[0059] Influence of the Astragalus Pharmaceutical Composition of the Invention on Colorectal Cancer

[0060] Experimental Method:

(1) First of all, poisonous dose test (the chemotherapy drug dose for inhibiting the cell growth and leaving 60˜70% of growth capability is selected for subsequent test)
(2) The cells are inoculated in 96-well plate and cultured for 24 hours.
(3) Test drugs at different concentrations are added in, the test concentrations of the r-APS are 0, 2 and 4 mg/ml, the test concentrations of the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose) are 0, 5 and 10 mg/ml.
(4) The dose with a poisoning effect on 35˜40% of individual cells is selected as chemotherapy drug dose.
(5) The cell viability is tested in 48 and 72 hours respectively after addition.
(6) Experiment on chemotherapeutic synergism of the r-APS and the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose):
(7) The cells are inoculated in 96-well plate and cultured for 24 hours.
(8) The r-APS or the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose) in combination with chemotherapy drug are cultured for 48 hours, the doses of the r-APS and the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose) are selected four poisonous doses for test, and then the cell viability is measured by MTS in 48 hours.

[0061] Poisonous dose test result: as shown in Table 1, when the dose of chemotherapy drug Regorafenib is 0.01 mM, the cell viability of the cancer cells can be poisoned to 60%, the condition after the cancer patient takes the chemotherapy drug is simulated, the experimental result of chemotherapeutic synergism of the r-APS and the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose) is shown in FIG. 4A.

TABLE-US-00001 TABLE 1 Cell viability (%) of cancer cells of colorectal cancer poisoned by chemotherapy drug Regorafenib at different concentrations Concentration 0 0.00001 0.0001 0.001 0.01 0.1 Repeat (mM) (mM) (mM) (mM) (mM) (mM) Repeat 1 1.054 1.108 1.102 1.095 0.646 0.094 Repeat 2 0.973 1.1 1.137 0.849 0.634 0.095 Repeat 3 0.991 1.1 0.985 0.906 0.637 0.089 Mean value 1.006 1.103 1.075 0.950 0.639 0.093 (MEAN) Standard 0.04 0.00 0.08 0.13 0.01 0.00 deviation (SD) Cell viability 100.0 109.6 106.8 94.4 63.5 9.2 (%)

[0062] As shown below in Table 2, the cancer cells of colorectal cancer (HCT116 cells) are added in the r-APS and cultured for 48 hours, the result shows that the growth of cancer cells is promoted slightly when the r-APS is used alone, meaning using the r-APS alone has no significant poisoning effect (as shown in FIG. 4B).

TABLE-US-00002 TABLE 2 Cell viability (%) of cancer cells of colorectal cancer (HCT116 cells) culture for 48 hours after adding the r-APS at different concentrations. Concentration 0 2 4 Repeat (mg/ml) (mg/ml) (mg/ml) Repeat 1 1.282 1.351 1.341 Repeat 2 1.290 1.381 1.342 Repeat 3 1.294 1.374 1.347 Mean value (MEAN) 1.289 1.369 1.343 Standard deviation (SD) 0.01 0.02 0.00 Cell viability (%) 100.00 106.21 104.24

[0063] As shown below in Table 3, the HCT116 has been treated with the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose) for 48 hours, the result shows that the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose) promotes the growth of cancer cells on the contrary, meaning the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose) has no significant poisoning effect (as shown in FIG. 4C).

TABLE-US-00003 TABLE 3 Cell viability (%) of cancer cells of colorectal cancer (HCT116 cells) culture for 48 hours after adding the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS + mannose) at different concentrations. Concentration 0 5 10 Repeat (mg/ml) (mg/ml) (mg/ml) Repeat 1 1.282 1.524 1.328 Repeat 2 1.290 1.524 1.361 Repeat 3 1.294 1.506 1.355 Mean value (MEAN) 1.289 1.518 1.348 Standard deviation (SD) 0.01 0.010 0.018 Cell viability (%) 100 117.80 104.60

[0064] As shown below in Table 4, the cancer cells of colorectal cancer (HCT116 cells) have been cultured for 48 hours after adding chemotherapy drug Regorafenib (0.01 mM) and the r-APS, the result shows that the growth of cancer cells is promoted when the effective concentration of the r-APS is 2 mg/mL, and the growth of cancer cells is inhibited slightly when the concentration is 4 mg/mL, meaning the r-APS in combination with chemotherapy drug has no significant poisoning effect (as shown in FIG. 4D).

TABLE-US-00004 TABLE 4 Cell viability (%) of cancer cells of colorectal cancer (HCT116 cells) culture for 48 hours after adding chemotherapy drug Regorafenib (0.01 mM) and the r-APS at different concentrations. Concentration 0 2 4 Repeat (mg/ml) (mg/ml) (mg/ml) Repeat 1 0.634 0.625 0.606 Repeat 2 0.646 0.710 0.614 Repeat 3 0.643 0.735 0.604 Mean value (MEAN) 0.641 0.690 0.608 Standard deviation (SD) 0.01 0.06 0.01 Cell viability (%) 71.4 76.9 67.8

[0065] As shown below in Table 5, the HCT116 has been cultured for 48 hours after adding chemotherapy drug Regorafenib (0.01 mM) and the astragalus pharmaceutical composition of the r-APS and the mannose (r-APS+mannose), the result shows that when the effective dose of the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose) is 10 mg/mL, the combination of chemotherapy drug can effectively reduce the viability of cancer cells, meaning the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose) in combination with chemotherapy drug has a significant poisoning effect (as shown in FIG. 4E).

TABLE-US-00005 TABLE 5 Cell viability (%) of cancer cells of colorectal cancer (HCT116 cells) culture for 48 hours after adding chemotherapy drug Regorafenib (0.01 mM) and the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS + mannose). Concentration 0 5 10 Repeat (mg/ml) (mg/ml) (mg/ml) Repeat 1 0.634 0.661 0.485 Repeat 2 0.646 0.670 0.495 Repeat 3 0.643 0.653 0.497 Mean value (MEAN) 0.641 0.661 0.492 Standard deviation (SD) 0.006 0.01 0.01 Cell viability (%) 71.43 73.70 54.90

[0066] The experimental results show that the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose) in combination with chemotherapy drug of the present invention can further reduce the viability of cancer cells of colorectal cancer by 16% compared with only using drug, so the therapeutic effect of chemotherapy drug can be enhanced effectively.

Example 4

[0067] Influence of the Astragalus Pharmaceutical Composition of the Present Invention on Ovarian Cancer

[0068] Experimental Method:

(1) Poisonous dose test (the chemotherapy drug dose for inhibiting the cell growth and leaving 60˜70% of growth capability is selected for subsequent test).
(2) The cells are inoculated in 96-well plate and cultured for 24 hours.
(3) Test drugs at different concentrations are added in, the test concentrations of the r-APS are 0, 2 and 4 mg/ml, the test concentrations of the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose) are 0, 5 and 10 mg/ml.
(4) The dose with a poisoning effect on 35-40% of individual cells is selected as chemotherapy drug dose.
(5) The cell viability is tested in 48 and 72 hours respectively after addition.
(6) Experiment on chemotherapeutic synergism of the r-APS and the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose).
(7) The cells are inoculated in 96-well plate and cultured for 24 hours.
(8) The r-APS or the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose) in combination with chemotherapy drug are cultured for 48 hours, the dose of the r-APS and the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose) is three poisonous doses for test, the cell viability is measured by MTS in 48 hours.

[0069] The poisonous dose test result is shown below in Table 6, when the dose of chemotherapy drug Olaparib is 0.7M, the cell viability of cancer cells can be poisoned to 60%, the condition after the cancer patient takes the chemotherapy drug is simulated, the experimental result of chemotherapeutic synergism of the r-APS and the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose) is shown in FIG. 5A.

TABLE-US-00006 TABLE 6 Cell viability (%) of ovarian cancer cell line (OVCAR cells) poisoned by chemotherapy drug Olaparib at different concentrations Concentration Repeat 0M 0.2M 0.4M 0.6M 0.8M 1M Repeat 1 0.984 0.984 0.895 0.752 0.531 0.214 Repeat 2 0.982 0.991 0.871 0.738 0.413 0.152 Repeat 3 0.969 0.976 0.885 0.715 0.486 0.184 Mean value 0.978 0.984 0.884 0.735 0.477 0.183 (MEAN) Standard 0.008 0.008 0.012 0.019 0.060 0.031 deviation (SD) Cell viability 100.00 100.55 90.32 75.13 48.72 18.74 (%)

[0070] The experimental result of chemotherapeutic synergism of the r-APS and the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose) is shown in Table 7, the ovarian cancer cell line (OVCAR cells) is cultured with the r-APS for 48 hours, the result shows that using the r-APS alone promotes the growth of cancer cells on the contrary, meaning using the r-APS alone has no significant poisoning effect (as shown in FIG. 5B)

TABLE-US-00007 TABLE 7 Cell viability (%) of ovarian cancer cell line (OVCAR cells) culture for 48 hours after adding the r-APS at different concentrations. Concentration 0 2 4 Repeat (mg/ml) (mg/ml) (mg/ml) Repeat 1 0.874 1.165 1.198 Repeat 2 0.873 1.215 1.237 Repeat 3 0.877 1.183 1.193 Mean value (MEAN) 0.875 1.188 1.209 Standard deviation (SD) 0.002 0.025 0.024 Cell viability (%) 100.0 135.8 138.3

[0071] As shown below in Table 8, the ovarian cancer cell line (OVCAR cells) has been cultured for 48 hours after adding the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose), the result shows that the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose) promotes the growth of cancer cells, meaning using the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose) alone has no significant poisoning effect (as shown in FIG. 5C).

TABLE-US-00008 TABLE 8 Cell viability (%) of ovarian cancer cell line (OVCAR cells) culture for 48 hours after adding the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS + mannose) at different concentrations Concentration 0 5 10 Repeat (mg/ml) (mg/ml) (mg/ml) Repeat 1 0.874 1.318 1.211 Repeat 2 0.877 1.351 1.251 Repeat 3 0.877 1.323 1.213 Mean value (MEAN) 0.876 1.331 1.225 Standard deviation (SD) 0.002 0.018 0.023 Cell viability (%) 100.2 152.1 140.1

[0072] As shown in Table 9, the ovarian cancer cell line (OVCAR cells) has been cultured with Olaparib (0.7 M) and the r-APS for 48 hours, the result shows that the r-APS in combination with chemotherapy drug Olaparib can effectively inhibit the viability of ovarian cancer cell line (OVCAR cells), so the r-APS in combination with chemotherapy drug has a significant poisoning effect (as shown in FIG. 5D).

TABLE-US-00009 TABLE 9 Cell viability (%) of ovarian cancer cell line (OVCAR cells) culture for 48 hours after adding Olaparib (0.7M) and the r-APS. Concentration 0 2 4 Repeat (mg/ml) (mg/ml) (mg/ml) Repeat 1 0.598 0.252 0.224 Repeat 2 0.584 0.244 0.216 Repeat 3 0.602 0.255 0.210 Mean value (MEAN) 0.595 0.250 0.217 Standard deviation (SD) 0.009 0.006 0.006 Cell viability (%) 60.189 25.337 21.930

[0073] As shown in Table 10, the ovarian cancer cell line (OVCAR cells) has been cultured with Olaparib (0.7M) and the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose) for 48 hours, the result shows that the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose) in combination with chemotherapy drug can effectively inhibit the cell viability of ovarian cancer cell line (OVCAR cells), so the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose) in combination with chemotherapy drug has a significant poisoning effect (as shown in FIG. 5E).

TABLE-US-00010 TABLE 10 Cell viability (%) of ovarian cancer cell line (OVCAR cells) culture for 48 hours after adding Olaparib (0.7M) and the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS + mannose) Concentration 0 5 10 Repeat (mg/ml) (mg/ml) (mg/ml) Repeat 1 0.598 0.220 0.183 Repeat 2 0.584 0.205 0.185 Repeat 3 0.632 0.227 0.175 Mean value (MEAN) 0.605 0.217 0.181 Standard deviation (SD) 0.025 0.011 0.005 Cell viability (%) 61.4 22.1 18.4

[0074] The experimental results show that the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose) in combination with chemotherapy drug of the present invention can further reduce the viability of cancer cells of colorectal cancer by 43% compared with only using drug, so the therapeutic effect of chemotherapy drug can be enhanced effectively.

[0075] To sum up, the astragalus pharmaceutical composition comprising the r-APS and the mannose (r-APS+mannose) in combination with chemotherapy drug of the present invention can reduce the cell viability of cancer cells by at least 16%, so the ability of chemotherapy drug to reduce the cell viability of cancer cells can be enhanced effectively, and the proliferation of tumor cells can be inhibited effectively, the chemotherapeutic effect is stronger than only using r-APS, even on drug resistant cancers, the therapeutic effect of chemotherapy drug can be maintained or enhanced.

[0076] All examples provided herein are intended for pedagogical purposes of aiding the reader in understanding the invention and the concepts contributed by the inventors to further the art, and are not to be construed as limitations to such specifically recited examples and conditions, nor does the organization of such examples in the specification relate to a showing of the superiority or inferiority of the invention. Although one or more embodiments of the present invention have been described in detail, it should be understood that the various changes, substitutions, and alterations could be made hereto without departing from the spirit and scope of the invention.

[0077] It is intended that the specification and examples be considered as examples only, with a true scope and spirit of the invention being indicated by the following claims.